Blood-Based Biomarkers of Neuroinflammation in Alzheimer’s Disease: A Central Role for Periphery?
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
Neuroinflammation represents a central feature in the development of Alzheimer’s disease (AD). The resident innate immune cells of the brain are the principal players in neuroinflammation, and their activation leads to a defensive response aimed at promoting β-amyloid (Aβ) clearance. However, it is now widely accepted that the peripheral immune system—by virtue of a dysfunctional blood–brain barrier (BBB)—is involved in the pathogenesis and progression of AD; microglial and astrocytic activation leads to the release of chemokines able to recruit peripheral immune cells into the central nervous system (CNS); at the same time, cytokines released by peripheral cells are able to cross the BBB and act upon glial cells, modifying their phenotype. To successfully fight this neurodegenerative disorder, accurate and sensitive biomarkers are required to be used for implementing an early diagnosis, monitoring the disease progression and treatment effectiveness. Interestingly, as a result of the bidirectional communication between the brain and the periphery, the blood compartment ends up reflecting several pathological changes occurring in the AD brain and can represent an accessible source for such biomarkers. In this review, we provide an overview on some of the most promising peripheral biomarkers of neuroinflammation, discussing their pathogenic role in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Interaction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947
Tracey, K. J. (2002) · Nature · doi:10.1038/nature01321 · Cited by 3,728
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437 · cited 1×
“Under physiological conditions, the BBB completely separates the CNS from the peripheral immune system [55]; however, proinflammatory cytokines, chemokines, NO, ROS and metalloproteinases (MMPs) are able to increase the BBB permeability, ultimately leading to the withdrawal of the immune privilege of the brain.”
BackgroundNicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., et al. (2003) · Nature · doi:10.1038/nature01339 · Cited by 3,228 · cited 1×
“Finally, the binding of ACh to α7 nicotinic acetylcholine receptors (α7nAChRs) expressed on macrophages inhibits proinflammatory cytokine synthesis and release, resulting in alleviated systemic inflammation [98] (Figure 1).”
BackgroundHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 1×
“Furthermore, in spite of all the advances in modern medicine, a definitive diagnosis of AD is still based on the post-mortem detection of characteristic pathologic brain lesions—Aβ plaques and neurofibrillary tangles—similar to those described by Alzheimer himself in 1907 [12,13].”
ResultMacrophage Cytokines: Involvement in Immunity and Infectious Diseases
Arango Duque, G., & Descoteaux, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00491 · Cited by 2,708
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102 · cited 1×
“The reduction of pericytes has also already been demonstrated in AD [50,51], together with the CSF increase of the soluble marker of pericytes damage, PDGFR-β [52].”
BackgroundFranceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M. P., Invidia, L., Celani, L., Scurti, M., et al. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.016 · Cited by 2,087
Stein, M., Keshav, S., Harris, N., & Gordon, S. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.1.287 · Cited by 1,960
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, E., & Trushina, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161088 · Cited by 1,750
Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 2×
“Neuroinflammation has been described in AD since the first characterization of the disorder [12] and is now well-recognized as a central feature in its development, contributing to the pathogenesis just as much as the pathological hallmarks [4].”
BackgroundAn english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“However, the long-standing exposure to Aβ—due to its increased production and accumulation over time—and inflammatory mediators (a result of the proinflammatory environment) induce a functional impairment in the microglia, whose phagocytic capacity becomes largely insufficient [34].”
BackgroundDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281 · cited 1×
“The reduction of pericytes has also already been demonstrated in AD [50,51], together with the CSF increase of the soluble marker of pericytes damage, PDGFR-β [52].”
BackgroundTakahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051 · cited 1×
“Attempts have been made in the last few years to get to an in vivo neuropathological diagnosis of the disease, independent from the clinical symptoms [15]; however, the latest recommendation is to opt of a comprehensive approach, encompassing both the clinical assessment and in vivo neuropathological evaluation [16].”
BackgroundCytokine-induced sickness behaviour: mechanisms and implications
Konsman, J. P., Parnet, P., & Dantzer, R. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02088-9 · Cited by 999 · cited 1×
“The existence of an intercommunication between the brain and the periphery is clearly supported by the occurrence of behavioral symptoms—a syndrome known as sickness behavior—in response to proinflammatory cytokines released in the framework of systemic inflammation [90].”
BackgroundSystemic inflammation and microglial activation: systematic review of animal experiments
Hoogland, I. C. M., Houbolt, C., van Westerloo, D. J., van Gool, W. A., & van de Beek, D. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0332-6 · Cited by 957 · cited 1×
“A single challenge induces only a transient activation, with the glial cells returning to their normal resting state shortly thereafter [81].”
BackgroundAdult mouse astrocytes degrade amyloid-β in vitro and in situ
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., & Husemann, J. (2003) · Nature Medicine · doi:10.1038/nm838 · Cited by 909
A new look at cerebrospinal fluid circulation
Brinker, T., Stopa, E., Morrison, J., & Klinge, P. (2014) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-11-10 · Cited by 819 · cited 1×
“As a matter of fact, the CSF reflects the status of the CNS, and, therefore, the pathological changes in the brain— determining alterations in the levels of various substances—are able to affect its composition accordingly [21].”
BackgroundRegulation of learning and memory by meningeal immunity: a key role for IL-4
Derecki, N. C., Cardani, A. N., Yang, C. H., Quinnies, K. M., Crihfield, A., Lynch, K. R., & Kipnis, J. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091419 · Cited by 800
Review: microglia of the aged brain: primed to be activated and resistant to regulation
Norden, D. M., & Godbout, J. P. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01306.x · Cited by 792
Passage of cytokines across the blood–brain barrier
Banks, W. A., Kastin, A. J., & Broadwell, R. D. (1996) · Neuroimmunomodulation · doi:10.1159/000097202 · Cited by 778
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767 · cited 1×
“Proinflammatory mediators released by chronically activated glial cells in the AD brain could compromise the integrity and permeability of the BBB [47].”
BackgroundTREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function
Zhao, Y., Wu, X., Li, X., Jiang, L.-L., Gui, X., Liu, Y., Sun, Y., Zhu, B., Piña-Crespo, J. C., Zhang, M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.031 · Cited by 763
Does neuroinflammation fan the flame in neurodegenerative diseases?
Frank-Cannon, T. C., Alto, L. T., McAlpine, F. E., & Tansey, M. G. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-47 · Cited by 751
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716 · cited 2×
“As a consequence, blood-based biomarkers appear to be easily implementable in clinical practice to monitor the disease progression or treatment efficacy over time [24].”
BackgroundJay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682
TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
Wyss-Coray, T., Lin, C., Yan, F., Yu, G.-Q., Rohde, M., McConlogue, L., Masliah, E., & Mucke, L. (2001) · Nature Medicine · doi:10.1038/87945 · Cited by 587
Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Watkins, L. R., Goehler, L. E., Relton, J. K., Tartaglia, N., Silbert, L., Martin, D., & Maier, S. F. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(94)11105-r · Cited by 516 · cited 1×
“Circulating proinflammatory cytokines, released by peripheral immune cells in response to pathogens and injury, are able to communicate with the CNS by crossing into the brain parenchyma—either passively, through leaky areas of the barrier, or by active transport systems (receptors on epithelial cells) [79]; alternati…”
BackgroundTranslocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repair
Chen, M.-K., & Guilarte, T. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.12.004 · Cited by 506
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504
A Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation
Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., & Landreth, G. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02665.2003 · Cited by 501
Reactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer’s Disease
Serrano-Pozo, A., Mielke, M. L., Gómez-Isla, T., Betensky, R. A., Growdon, J. H., Frosch, M. P., & Hyman, B. T. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.047 · Cited by 488 · cited 1×
“The pathological accumulation of Aβ and NFT in the brain is considered the principal trigger for neuroinflammatory responses in AD, inducing the activation of resident glial cells [28].”
BackgroundMicrovascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases
Togo, T., Akiyama, H., Iseki, E., Kondo, H., Ikeda, K., Kato, M., Oda, T., Tsuchiya, K., & Kosaka, K. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00496-9 · Cited by 481 · cited 1×
“A number of reports have confirmed an increase of CD4+ and CD8+ T cells in the brains, blood and CSF of AD patients [70,71].”
BackgroundCosenza‐Nashat, M., Zhao, M. ‐., Suh, H. ‐., Morgan, J., Natividad, R., Morgello, S., & Lee, S. C. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.01006.x · Cited by 459
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease
Yamazaki, Y., & Kanekiyo, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091965 · Cited by 451
Michelucci, A., Heurtaux, T., Grandbarbe, L., Morga, E., & Heuschling, P. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.02.003 · Cited by 411
Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice
Krstic, D., Madhusudan, A., Doehner, J., Vogel, P., Notter, T., Imhof, C., Manalastas, A., Hilfiker, M., Pfister, S., Schwerdel, C., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-151 · Cited by 400
Shen, X.-N., Niu, L.-D., Wang, Y.-J., Cao, X.-P., Liu, Q., Tan, L., Zhang, C., & Yu, J.-T. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319148 · Cited by 388
Zhong, L., Xu, Y., Zhuo, R., Wang, T., Wang, K., Huang, R., Wang, D., Gao, Y., Zhu, Y., Sheng, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09118-9 · Cited by 371
Schmid, C. D., Sautkulis, L. N., Danielson, P. E., Cooper, J., Hasel, K. W., Hilbush, B. S., Sutcliffe, J. G., & Carson, M. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01243.x · Cited by 351
In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease
Kreisl, W. C., Lyoo, C. H., McGwier, M., Snow, J., Jenko, K. J., Kimura, N., Corona, W., Morse, C. L., Zoghbi, S. S., Pike, V. W., et al. (2013) · Brain · doi:10.1093/brain/awt145 · Cited by 350
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303
Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2
Ulrich, J. D., Finn, M. B., Wang, Y., Shen, A., Mahan, T. E., Jiang, H., Stewart, F. R., Piccio, L., Colonna, M., & Holtzman, D. M. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-20 · Cited by 302
Wunderlich, P., Glebov, K., Kemmerling, N., Tien, N. T., Neumann, H., & Walter, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.517540 · Cited by 296
Intrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease
Galimberti, D., Schoonenboom, N., Scheltens, P., Fenoglio, C., Bouwman, F., Venturelli, E., Guidi, I., Blankenstein, M. A., Bresolin, N., & Scarpini, E. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.538 · Cited by 289
Glial activation and inflammation along the Alzheimer’s disease continuum
Nordengen, K., Kirsebom, B.-E., Henjum, K., Selnes, P., Gísladóttir, B., Wettergreen, M., Torsetnes, S. B., Grøntvedt, G. R., Waterloo, K. K., Aarsland, D., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1399-2 · Cited by 274 · cited 1×
“As a consequence, a certain degree of neuroinflammation would already be detectable in the prodromal phase of AD, even before Aβ and NFT deposition [89].”
BackgroundApplication of Metabolomics in Alzheimer’s Disease
Wilkins, J. M., & Trushina, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00719 · Cited by 268
Real-Time In Vivo Imaging Reveals the Ability of Monocytes to Clear Vascular Amyloid Beta
Michaud, J.-P., Bellavance, M.-A., Préfontaine, P., & Rivest, S. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.010 · Cited by 257
TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice
Frank, S., Burbach, G. J., Bonin, M., Walter, M., Streit, W., Bechmann, I., & Deller, T. (2008) · Glia · doi:10.1002/glia.20710 · Cited by 247
ISHIZUKA, K., KIMURA, T., IGATA‐YI, R., KATSURAGI, S., TAKAMATSU, J., & MIYAKAWA, T. (1997) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1997.tb02375.x · Cited by 245 · cited 2×
“In AD, the development of neuroinflammation is accompanied by a generalized upregulation of plaque-associated chemokines and chemokine receptors, leading to peripheral monocyte recruitment and glial cell activation [62,129].”
BackgroundKuhlmann, A. C., & Guilarte, T. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741694.x · Cited by 215
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease
Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., Scalabrini, D., Clerici, F., Mariani, C., Bresolin, N., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.007 · Cited by 209
Lananna, B. V., McKee, C. A., King, M. W., Del-Aguila, J. L., Dimitry, J. M., Farias, F. H. G., Nadarajah, C. J., Xiong, D. D., Guo, C., Cammack, A. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax3519 · Cited by 201
T-Cells in Alzheimer's Disease
Town, T., Tan, J., Flavell, R. A., & Mullan, M. (2005) · NeuroMolecular Medicine · doi:10.1385/nmm:7:3:255 · Cited by 183 · cited 1×
“the brain through the damaged BBB or exerting their function from the periphery (via cytokine secretion) [73].”
BackgroundBlood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible
Thambisetty, M., & Lovestone, S. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.84 · Cited by 182
Bermejo, P., Martín-Aragón, S., Benedí, J., Susín, C., Felici, E., Gil, P., Ribera, J. M., & Villar, Á. M. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.02.002 · Cited by 178
Change in risk of Alzheimer disease over time
Hebert, L. E., Bienias, J. L., Aggarwal, N. T., Wilson, R. S., Bennett, D. A., Shah, R. C., & Evans, D. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f0754f · Cited by 158 · cited 1×
“Age being the main risk factor for the disease, the marked increase in life expectancy is likely to determine a dramatic rise in the number of AD patients over the years, with substantial consequences on the public health worldwide [1].”
BackgroundKester, M. I., Teunissen, C. E., Sutphen, C., Herries, E. M., Ladenson, J. H., Xiong, C., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0142-1 · Cited by 146
IL-4-Induced Selective Clearance of Oligomeric β-Amyloid Peptide1–42 by Rat Primary Type 2 Microglia
Shimizu, E., Kawahara, K., Kajizono, M., Sawada, M., & Nakayama, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6503 · Cited by 143
Interplay between Brain Pericytes and Endothelial Cells in Dementia
Procter, T. V., Williams, A., & Montagne, A. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2021.07.003 · Cited by 106 · cited 1×
“The BBB comprises various elements, collectively known as the neurovascular unit (NVU), including—besides endothelial cells—pericytes, astrocytes and oligodendrocytes [48].”
BackgroundLiu, Y.-J., Guo, D.-W., Tian, L., Shang, D.-S., Zhao, W.-D., Li, B., Fang, W.-G., Zhu, L., & Chen, Y.-H. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.024 · Cited by 92
Clark, C., Lewczuk, P., Kornhuber, J., Richiardi, J., Maréchal, B., Karikari, T. K., Blennow, K., Zetterberg, H., & Popp, J. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00805-8 · Cited by 88
Söllvander, S., Ekholm-Pettersson, F., Brundin, R.-M., Westman, G., Kilander, L., Paulie, S., Lannfelt, L., & Sehlin, D. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150236 · Cited by 60 · cited 1×
“In addition, the number of B cells was found significantly increased in the blood of AD patients compared to healthy controls (given their role in antibody secretion, direct tissue infiltration is not necessarily required) [72].”
BackgroundTreatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches
Galimberti, D., & Scarpini, E. (2010) · Current Aging Science · doi:10.2174/1874609811003010046 · Cited by 51 · cited 1×
“Differently, the so-called “disease-modifying therapies” able to act on the cause and evolution of the disease by interfering with its pathogenesis are more effective when the brain damage is still restrained [18].”
Background
Cited by
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review
Pozzi, F. E., Conti, E., Appollonio, I., Ferrarese, C., & Tremolizzo, L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.998224 · Cited by 36
Self-citationFraile-Ramos, J., Garrit, A., Reig-Vilallonga, J., & Giménez-Llort, L. (2023) · Cells · doi:10.3390/cells12111517 · Cited by 26
Metadata
- Authors
- Angiulli, F., Conti, E., Zoia, C. P., Da Re, F., Appollonio, I., Ferrarese, C., & Tremolizzo, L.
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2021-08-24
- Volume
- 11
- Issue
- 9
- Pages
- 1525
- ISSN
- 2075-4418 (ISSN-L)
- OpenAlex
- W3195585427
- Cited by
- 52
- References
- 72
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.